Academic yr: <<< Previous
2024
2025
2026
Department of Medical Oncology
|
■ Summary
|
|
Medical oncology is an internal medicine subspecialty dedicated to the diagnosis, treatment, and long-term management of cancer through systemic therapies such as chemotherapy, molecularly targeted therapy, immunotherapy, and investigational therapy. Medical oncologists are responsible for assessing disease stage and prognosis, formulating individualized treatment plans, and managing adverse effects while also providing survivorship care. We collaborate closely with surgeons, radiation oncologists, pathologists, nurses, pharmacists, and social workers to deliver comprehensive, multidisciplinary cancer care. In addition, we play a leading role in the design and conduct of clinical trials, thereby contributing to the implementation of novel therapies. Medical oncology also emphasizes research—particularly translational research—and education, establishing its position as a discipline that advances science, clinical practice, and training as three inseparable pillars.
Clinical Practice
Our department provides systemic therapy for a wide range of solid tumors, including gastrointestinal, breast, lung, gynecologic, and genitourinary cancers. Our practice incorporates cutting-edge treatments such as molecularly targeted agents, immune checkpoint inhibitors, and antibody-drug conjugates (ADCs). We also emphasize cancer genomic medicine and supportive care—including pain management, antiemetic therapy, and interventions for cancer cachexia—to improve patients’ quality of life. Through collaboration with palliative care and genetic medicine services, as well as partnerships with regional medical institutions, we deliver state-of-the-art treatments broadly and equitably.
Research Activities
Our research activities span three domains: clinical, translational, and basic science.
Clinical Research
• Active participation in multicenter phase I–III clinical trials
• Development of personalized medicine strategies based on biomarkers
• Exploration of novel therapies for rare and refractory tumors
• Evaluation of efficacy and safety of immunotherapies, targeted agents, and ADCs
Translational Research
• Identification of predictive biomarkers through analysis of tumor tissues and circulating factors
• Integration of genomic data with clinical outcomes
• Investigation of the tumor microenvironment, including immune cell infiltration and cytokine networks
• Elucidation of drug resistance mechanisms and development of strategies to overcome them
Basic Research
• Molecular studies of cancer-related genetic alterations and therapeutic sensitivity
• Investigation of tumor progression mechanisms mediated by miRNAs and epigenomic changes
• Pathophysiological research on cancer cachexia and tumor metabolism
The outcomes of these research activities have been disseminated in international peer-reviewed journals and presented at scientific meetings worldwide, contributing to the advancement of medical oncology and its clinical applications. Moreover, physician-initiated trials and academic–industry collaborations have generated that directly foster the development and clinical implementation of innovative therapies.
|
|
To the top
|
|
■ Research grants & projects
|
■ Research works
| Journal |
Book |
Presentation |
Other presentations |
| Japanese | English |
Japanese | English |
Domestic | international |
| First author | Corresponding
Author | Co-author | First author | Corresponding
Author | Co-author |
First author | Co-author | First author | Co-author |
Presenter | Co-presenter | Presenter | Co-presenter |
Presenter | Co-presenter |
| 0 | 0 | 0 | 0 | 0 | 3 |
0 | 1 | 0 | 0 |
0 | 0 |
0 | 0 |
0 | 0 |
|
|
To the top
|
|
■ Published papers
|
Original article
|
|
1.
|
Kota Ishioka, Naomi Hayashi, Naoki Miyazaki, Akito Dobashi, Eri Habano, Asami Kuga, Keika Kaneko, Hiromi Arakawa, Yuko Minoura, Ippei Fukada, Masumi Yamazaki, Naoki Fukuda, Akemi Kataoka, Toshimi Takano, Masayuki Watanabe, Shunji Takahashi, Arisa Ueki, Makiko Ono：
Germline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor-normal paired sequencing study.
International journal of clinical oncology
：7，12
, 2026.7
DOI:10.1007/s10147-026-03155-3
|
|
2.
|
Naomi Hayashi, Naoki Miyazaki, Ippei Fukada, Masumi Yamazaki, Naoki Fukuda, Arisa Ueki, Akemi Kataoka, Toshimi Takano, Masayuki Watanabe, Seiichi Mori, Makiko Ono, Shunji Takahashi：
Tumor Lineage–Specific Disparities in Access to Genome-Matched Therapies Among Adolescents and Young Adults in Japan: A Nationwide Genomic Profiling Study.
JCO Oncology Advances
：5,9
, 2026.7
DOI:10.1200/OA-26-00019
|
|
Review article
|
|
1.
|
Makiko Ono, Yasuaki Sagara, Toshiyuki Ishiba, Yukinori Ozaki, Takehiko Sakai, Hideo Shigematsu, Akihiko Shimomura, Kazuki Sudo, Kaori Terata, Yoichi Naito, Kazuki Nozawa, Fumikata Hara, Tomomi Fujisawa, Tadahiko Shien：
De-escalation of perioperative systemic therapy for early breast cancer.
Japanese journal of clinical oncology
：1-6
, 2026.8
DOI:10.1093/jjco/hyag131
|
|
To the top
|
|
■ Books
|
1.
|
高野利実、三浦裕司、内野慶太、西條朝貴、小宮山知夏、須河恭敬、宮本信吾、山中太郎、宮本篤、三ツ村隆弘、上坂義和、山口雄、奥村浩基、長谷川詠子、福原傑、古谷賢人、伊東直哉、岸本修一、小畑亮、三武さわ、下村昭彦、渡辺祥伍、北野敦子、春田周宇介、厚坊浩史、清水研、上野尚雄、小野麻紀子、河野遼、関根章成、陶山浩一、鈴木優矢、加藤達也、竹村弘司、北野滋久：
AYA世代の妊孕性温存.
ハイリスク患者のがん薬物療法プラクティスー診療科の枠を超えた学際的コラボー
247.
南江堂,
東京,
2026.8
|
|
To the top
|
|
